Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Michael S. Ip, MD, discusses a real-world study in eyes with geographic atrophy due to nonexudative age-related macular degeneration.
Ip, of Doheny Eye Center UCLA Arcadia, said the efficacy and safety findings for Syfovre (pegcetacoplan injection, Apellis) were “reassuring.” Results showed the rate of adverse effects was low.
“At least in one large private practice setting, the real-world results quite mirror what were seen in the phase 3 OAKS and DERBY clinical trials,” he told Healio.